mortality/aging
• 50% of mice are dead by 14 months of age unlike wild-type mice
|
endocrine/exocrine glands
• at 3 and 12 months, the vasculature of some islets is abnormal with dilation of blood vessels and intense tortuosity unlike in wild-type mice
• however, treatment with sunitinib decreases in islet vascularity
|
• as early as 5 to 6 months
|
• as early as 5 to 6 months
|
• by 10 to 12 months of age, mice develop insulinoma that are filled with blood islands or lacunae unlike wild-type mice
• however, mice do not develop gastrinoma unlike in other MEN1 models
|
• mice exhibit more proliferating cells within their islets compared with wild-type mice
• however, proliferation of exocrine cells is normal and treatment with sunitinib decreases islet cell proliferation
|
homeostasis/metabolism
• at 10 months of age
|
• starting at 5 months of age
|
neoplasm
• by 10 to 12 months of age, mice develop insulinoma that are filled with blood islands or lacunae unlike wild-type mice
• however, mice do not develop gastrinoma unlike in other MEN1 models
|
cardiovascular system
• at 3 and 12 months, the vasculature of some islets is abnormal with dilation of blood vessels and intense tortuosity unlike in wild-type mice
• however, treatment with sunitinib decreases in islet vascularity
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
multiple endocrine neoplasia type 1 | DOID:10017 |
OMIM:131100 |
J:146440 |